{
    "key_points": [
        "Over 6.8 million doses of the Johnson & Johnson COVID-19 vaccine have been administered in the U.S.",
        "CDC and FDA are investigating six reported cases of a rare and severe type of blood clot (CVST) combined with low levels of blood platelets (thrombocytopenia) following vaccination.",
        "All six cases occurred among women aged 18 to 48, with symptoms appearing 6 to 13 days post-vaccination.",
        "The treatment for this type of blood clot is different, with the usual treatment of heparin potentially being dangerous.",
        "An Advisory Committee on Immunization Practices (ACIP) meeting is scheduled to review these cases and assess their significance.",
        "A temporary pause on the use of the Johnson & Johnson vaccine is recommended out of an abundance of caution.",
        "The pause is also to alert the healthcare provider community about the potential adverse events and proper management.",
        "These adverse events are currently viewed as extremely rare.",
        "Individuals who received the J&J vaccine and develop severe symptoms are advised to seek medical care and report adverse events.",
        "Additional information will be provided by CDC and FDA at a media briefing, with a recording available on the FDA's YouTube channel."
    ],
    "spokespersons": [],
    "article_type": "government agency statement",
    "dateline": "",
    "audience": "general public",
    "stance": "neutral"
}